Respiratory Syncytial Virus Diagnostics Market To Reach $8.70 Billion By 2030

Respiratory Syncytial Virus Diagnostics Market Growth & Trends

The global respiratory syncytial virus diagnostics market size is estimated to reach USD 8.70 billion by 2030, expanding at a CAGR of 5.81% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increasing neonatal population suffering from respiratory conditions including RSV infections and supportive initiatives for diagnosis of newborns by the healthcare providers are expected to be vital impact rendering drivers for RSV diagnostics market.

According to the statistics provided by the WHO, hospitalization of over 150,000 children (below the age of five) and about 14,000 deaths in geriatric patients occurred in the U.S. in 2014 due to RSV infections. This is anticipated to trigger demand for testing of these conditions over the forecast period.

Furthermore, the global birth rate as of 2014 is 18.7 births per 1,000 individuals, which is predicted to increase the infant population substantially over the next seven years. According to the statistics, it is estimated that about 134.2 million births took place in 2014, which are prone to RSV infections and require diagnosis, thus forming a large market base.

In 2010, Save Babies Through Screening Foundation (SBTS) entered in a partnership with World Solutions Against Infectious Disease (WSAID) as an attempt to promote higher screening of newborns for infectious diseases, metabolic disorders, and hearing disabilities.

 Request a free sample copy or view report summary: Respiratory Syncytial Virus Diagnostics Market Report

Respiratory Syncytial Virus Diagnostics Market Report Highlights

•  Chromatographic immunoassay segment dominated the market with a share of 27.38% in 2024 over the next seven years owing to their higher specificity than molecular diagnostic products. The commercially available test kits include Binax Now RSV, QuickLab RSV Test, Remel Xpect, and RSV Respi-Strip.

• Hospitals segment dominated the market with a share of 41.09% in 2024 and is anticipated to grow at fastest growth rate over the forecast period. Increasing demand for home care diagnostic devices by patients is anticipated to drive growth of the segment over the next seven years.

• North America is anticipated to dominate the market and contribute a revenue share of over 41.18% by 2024. Rising awareness among the population base and favorable initiatives by the government agencies such as the WHO, PAHO, and WSAID to initiate and implement newborn screening are expected to drive growth.

• Key players of the market include Novartis AG, Abbott, BD and Company, Ortho Clinical Diagnostics, Roche Diagnostics, Abbott Laboratories, and Thermo Fisher Scientific Inc. CLIA waiver and launch of RSV assays by companies like Roche Diagnostics, Becton Dickinson and Company, and Alere Inc. are expected to boost market growth over the forecast period.

Respiratory Syncytial Virus Diagnostics Market Segmentation

Grand View Research has segmented the global respiratory syncytial virus diagnostics market based on product, end use, and region:

Respiratory Syncytial Virus Diagnostics Product Outlook (Revenue, USD Billion, 2018 - 2030)

• Direct Fluorescent Antibody (DFA) Method

• Rapid Antigen Diagnostic Test (RADTs)

• Molecular Diagnostics

• Chromatographic Immunoassay

  • Gravity Driven Test

  • Oligochromatography (OC)

• Diagnostic Imaging

• Gel Microdroplets

• Flow Cytometry

• Others

Respiratory Syncytial Virus Diagnostics End use Outlook (Revenue, USD Billion, 2018 - 2030)

• Hospitals

• Laboratory

• Clinics

• Homecare

Respiratory Syncytial Virus Diagnostics Regional Outlook (Revenue, USD Billion, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in Respiratory Syncytial Virus Diagnostics Market

• BD (Becton, Dickinson, and Company)

• Novartis AG

• Abbott

• QuidelOrtho Corporation

• Thermo Fisher Scientific Inc.

• Bio-Rad Laboratories, Inc.

• F. Hoffmann-La Roche Ltd.

• BIOMÉRIEUX

• DiaSorin S.p.A.

• Merck KGaA

• Coris BioConcept

• Siemens Healthcare S.A.

• Quest Diagnostics Incorporated